Suppliers / Chongqing Land Tower Pharmaceutical

Chongqing Land Tower Pharmaceutical

China Updated 9 July 2026

Chongqing Land Tower Pharmaceutical is an API manufacturer based in China. It holds 2 active US drug master files across a filed portfolio of 3 molecules.

2
active US DMFs
0
valid CEPs
0
registered plants
0
filings across 0 regulators

What they file, and where

Molecule Regulators Docs
Clindamycin SFDA (Saudi Arabia) 1
Methylnaltrexone US FDA 1
Naltrexone US FDA 1

Also appears on these molecule pages

Naltrexone API Clindamycin API

Questions about Chongqing Land Tower Pharmaceutical

Does Chongqing Land Tower Pharmaceutical hold a US DMF or a CEP?
Chongqing Land Tower Pharmaceutical holds 2 active US drug master files. A drug master file is a submission to the FDA describing how an ingredient is made; a CEP is the EDQM's certificate that the substance meets its European Pharmacopoeia monograph. Both are filings rather than approvals.
What does Chongqing Land Tower Pharmaceutical make?
3 molecules are on record against Chongqing Land Tower Pharmaceutical, including Clindamycin, Methylnaltrexone and Naltrexone. Each links through to that molecule's full manufacturer list.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Chongqing Land Tower Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Comparable suppliers

Specgx shares 1 molecule Aspen Oss shares 1 molecule Macfarlan Smith shares 1 molecule Sthree Chemicals shares 1 molecule Noramco shares 1 molecule

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability